Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 12, 2008, Pages 1279-1287

  Herrmann, Nathan ^a,c   Gauthier, Serge ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; HALOPERIDOL; LORAZEPAM; MEMANTINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR THERAPY; CAREGIVER SUPPORT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DIARRHEA; DRUG FATALITY; FALLING; HUMAN; NAUSEA; NUTRITION; PATIENT ASSESSMENT; REVIEW; SEDATION; SIDE EFFECT; VOMITING;

EID: 57349130740     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.070804     Document Type: Review

References (72)

1. Canadian Study of Health and Aging. Study methods and prevalence of dementia. CMAJ 1994;150:899-913.
2. Patterson CJ, Gauthier S, Bergman H, et al. Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. CMAJ 1999;160:1738-42.
3. Chertkow H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ 2008;178:316-21.
4. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
5. Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007;19:421-56.
6. Boller F, Verny M, Hugonot-Diener L, et al. Clinical features and assessment of severe dementia. A review. Eur J Neurol 2002;9:125-36.
7. Scherder E, Oosterman J, Swaab D, et al. Recent developments in pain in dementia. BMJ 2005;330:461-4.
8. Allen NH, Burns A, Newton V, et al. The effects of improving hearing in dementia. Age Ageing 2003;32:189-93.
9. Magri F, Borza A, del Vecchio S, et al. Nutritional assessment of demented patients: a descriptive study. Aging Clin Exp Res 2003;15:148-53.
10. Nandy s, Parsons S, Cryer C, et al. Development and preliminary examination of the predictive validity of the Falls Risk Assessment Tool (FRAT) for use in primary care. J Public Health 2004;26:138-43.
11. Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2004;18:S17-23.
12. Kettl P. Helping families with end-of-life care in Alzheimer's disease. J Clin Psychiatry 2007;68:445-50.
13. Mittelman MS, Roth DL, Coon DW, et al. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatry 2004;161:850-6.
14. Knopman DS, Berg JD, Thomas R, et al. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology 1999;52:714-8.
15. Hébert R, Dubois MF, Wolfson C, et al. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2001;56:M693-9.
16. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-7.
17. Lanctot KL, Bowles SK, Herrmann N, et al. Drugs mimicking dementia. Dementia symptoms associated with psychotropic drugs in institutionalised cognitively impaired patients. CNS Drugs 2000;14:381-90.
18. Feldman HH, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 2008;178:825-36.
19. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021.
20. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003;51:1305-17.
21. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005;20:301-14.
22. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006;166:2182-8.
23. Spira AP, Edelstein BA. Behavioral interventions for agitation in older adults with dementia: an evaluative review. Int Psychogeriatr 2006;18:195-225.
24. Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 1997;52:159-66.
25. Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev 2006;(1)CD003477.
26. Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006;18:623-30.
27. Svansdottir HB, Snaedal J. Music therapy in moderate and severe dementia of Alzheimer's type: a case-control study. Int Psychogeriatr 2006;18:613-21.
28. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608.
29. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70.
30. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.
31. Health Canada endorsed important safety information on atypical antipsychotic drugs and dementia: increased mortality associated with the use of atypical antipsychotic drugs in elderly patients with dementia [Dear Health Care Professional letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2005. Available: www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/prof/_2005/atyp-antipsycho_hpc-cps-eng.php (accessed 2008 Sept 25).
32. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
33. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.
34. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005;66:1090-6.
35. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
36. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004;12:437-9.
37. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
38. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86.
39. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
40. Katz I, de Deyn PP, Mintzer J, et al. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007;22:475-84.
41. Van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2002;14:197-210.
42. Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebocontrolled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004;65:114-9.
43. Herrmann N, Lanctot KL. Pharmacological management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007;52:630-46.
44. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias, Second Edition. Am J Psychiatry 2007;164:1-56.
45. Olin J, Schneider L, Katz I, et al. Provisional diagnostic criteria for depression of Alzheimer Disease. Am J Geriatr Psychiatry 2002;10:125-8.
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington (DC): American Psychiatric Press; 2000. p. 369-76.
47. Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 2007;52:248-55.
48. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015-22.
49. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
50. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
51. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27.
52. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65.
53. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69.
54. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 Jan 25;(1):CD005593.
55. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.
56. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
57. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
58. Jones RW, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:258-62.
59. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24:20-7.
60. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:138-45.
61. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006;20:263-8.
62. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19:919-25.
63. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64.
64. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005;65:481-2.
65. Monastero R, Camarda C, Pipia C, et al. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007;78:546. Epub 2006 Oct 9.
66. Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007;52:519-26.
67. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33.
68. Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18:282-4.
69. Simpson S, Beavis D, Leddy A, et al. Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatr Bull 2005;29:410-2.
70. Herrmann N. Treatment of moderate to severe Alzheimer's disease: rationale and trial designs. Can J Neurol Sci 2007;34:S103-8.
71. Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006;367:1031-2.
72. Herrmann N, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned? Drug Saf 2006;29:833-43.